Primary Drug-Resistance Pattern and Trend in Elderly Tuberculosis Patients in Shandong, China, from 2004 to 2019

References

• World Health Organization. Global Tuberculosis Report 2019. Geneva: World Health Organization; 2019 Available from: http://www.who.int/tb/publications/global_report/en. Accessed 1019, 2020.
   Google Scholar
• World Health Organization. Global Tuberculosis Report 2018. Geneva: WorldHealth Organization; 2018 Available from: http://www.who.int/tb/publications/global_report/en. Accessed 1019, 2020.
   Google Scholar
• GBD Tuberculosis collaborators. Global, regional, and national burden of tuberculosis, 1990–2016: results from the global burden of diseases, injuries, and risk factors 2016 Study. Lancet Infect Dis. 2018;18:1329–1349. doi:10.1002/hed.2637830507459
   PubMed Web of Science ®Google Scholar
• Dheda K, Gumbo T, Maartens G; GBD Tuberculosis collaborators. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291–360. doi:10.1016/S2213-2600(17)30079-6
   Web of Science ®Google Scholar
• United Nations Development Program. china human development report 2013 Available from https://www.cn.undp.org/content/china/en/home/library/human_development/china-national-human-development-report-2013.html. Accessed 1019, 2020.
   Google Scholar
• Negin J, Abimbola S, Marais BJ. Tuberculosis among older adults – time to take notice. Int J Infect Dis. 2015;32:135–137. doi:10.1016/j.ijid.2014.11.01825809769
   PubMed Web of Science ®Google Scholar
• Kyu HH, Maddison ER, Henry NJ; GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18(3):261–284. doi:10.1016/S1473-3099(17)30703-X29223583
   PubMed Web of Science ®Google Scholar
• Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar J-W. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018. doi:10.1016/j.jinf
   Google Scholar
• Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5:a017863. doi:10.1101/cshperspect.a01786325918181
   PubMed Web of Science ®Google Scholar
• Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? Tuber Lung Dis. 1995;76:487–492. doi:10.1016/0962-8479(95)90523-58593368
   PubMedGoogle Scholar
• Cheng J, Sun Y-N, Zhang C-Y, et al. Incidence and risk factors of tuberculosis among the elderly population in China: a prospective cohort study. Infect Dis Poverty. 2020;9(1):13. doi:10.1186/s40249-019-0614-932005290
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang H, Liu J, et al. Mycobacterium tuberculosis infection among the elderly in 20 486 rural residents aged 50–70 years in Zhongmu County, China. Clin Microbiol Infect. 2019;25(9):1120–1126. doi:10.1016/j.cmi.2019.01.02130738995
   PubMed Web of Science ®Google Scholar
• Zhang C-Y, Zhao F, Xia -Y-Y, et al. Prevalence and risk factors of active pulmonary tuberculosis among elderly people in China: a population based cross-sectional study. Infect Dis Poverty. 2019;8(1):7. doi:10.1186/s40249-019-0515-y30654836
   PubMed Web of Science ®Google Scholar
• Jing H, Wang H, Wang Y, et al. Prevalence of nontuberculous mycobacteria infection, China, 2004–2009. Emerging Infect Dis. 2012;18(3):527–528. doi:10.3201/eid1803.110175
   Web of Science ®Google Scholar
• Zhou Y, van den Hof S, Wang S, et al. Association between genotype and drug resistance profiles of Mycobacterium tuberculosis strains circulating in China in a national drug resistance survey. PLoS One. 2017;12(3). doi:10.1371/journal.pone.0174197
   Web of Science ®Google Scholar
• World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis. 5th ed. Geneva: TheOrganization; 2015 https://www.who.int/tb/publications/2015/drs_guidelines/en. Accessed 1019, 2020.
   Google Scholar
• Van RA, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet. 2000;356(9223):22–25. doi:10.1016/s0140-6736(00)02429-610892760
   PubMed Web of Science ®Google Scholar
• Chiang C-Y, Schaaf HS. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2010;14(6):672–682. doi:10.1016/S0140-6736(19)31882-320487603
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definitions and Reporting Framework for Tuberculosis—2013 Revision. Vol. 2 Geneva: World Health Organization; 2013b https://www.who.int/tb/publications/definitions/en/. Accessed 1019, 2020.
   Google Scholar
• Abuaku B, Tan H, Li X, Chen M, Huang X. Treatment default and death among tuberculosis patients in Hunan, China. Scand J Infect Dis. 2010;42(4):281–287. doi:10.3109/0036554090349372320100113
   PubMed Web of Science ®Google Scholar
• Cantalice Filho JP, Boia MN, Sant Anna CC. Analysis of the treatment of pulmonary tuberculosis in elderly patients at a university hospital in Rio de Janeiro, Brazil. J Bras Pneumol. 2007;33 691–698. doi: 10.1590/s1806-3713200700060001318200370
   PubMedGoogle Scholar
• Bele S, Jiang W, Lu H 1, et al. Population aging and migrant workers: bottlenecks in tuberculosis control in Rural China. PLoS One. 2014;9(2):e88290. doi:10.1371/journal.pone.008829024498440
   PubMed Web of Science ®Google Scholar
• Koseła MK. Tuberculosis in poland in 2017*. Przegl Epidemiol. 2019;73(2):211–226. doi:10.32394/pe.73.2031385679
   PubMedGoogle Scholar
• Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLoS Med. 2009;6(12):e1000199. doi:10.1371/journal.pmed.100019920027210
   PubMed Web of Science ®Google Scholar
• Simet SM, Joseph H. Sisson. Alcohol’s effects on lung health and immunity. Alcohol Health Res World. 2015;37(2):199–208.
   Google Scholar
• Seonadh MO, Leary MM, Chew WM, et al. Cigarette smoking impairs human pulmonary immunity to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2014;190(12). doi:10.1164/rccm.201407-1385OC
   Web of Science ®Google Scholar
• Peleg AY, Thilak Weerarathna JS, McCarthy TM, Davis E. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23(1):3–13. doi:10.1002/dmrr.68216960917
   PubMed Web of Science ®Google Scholar
• van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010;35(1):27–33. doi:10.1183/09031936.0007290920044459
   PubMed Web of Science ®Google Scholar
• Silva DR, Muñoz-Torrico M, Duarte R, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018;44(2):145–152. doi:10.1590/s1806-3756201700000044329791552
   PubMed Web of Science ®Google Scholar
• Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: a systematic review. PLoS One. 2017;12(4):e0175925. doi:10.1371/journal.pone.017592528430796
   PubMed Web of Science ®Google Scholar
• Inghammar M, Löfdahl CG, Winqvist N, Ljungberg B, Egesten A, Engström G. Impaired pulmonary function and the risk of tuberculosis: a population-based cohort study. Eur Respir J. 2011;37(5):May. doi:10.1183/09031936.00091110
   Web of Science ®Google Scholar
• Müller L, PawelecG. Aging and immunity – impact of behavioral intervention. Brain Behav Immun. 2014;39:8–22. doi:10.1016/j.bbi.2013.11.01524315935
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu S, Wang L, et al. National survey of drug resistant tuberculosis in China. N Engl J Med. 2012;366:2161–2170. doi:10.1056/NEJMoa110878922670902
   PubMed Web of Science ®Google Scholar
• Liao S, Cai C, Huo F-M, et al. Trends in drug-resistant tuberculosis in China: data from a clinical tuberculosis centre. Int J Tuberc Lung Dis. 2017;21(9):990–995. doi:10.5588/ijtld.17.008628826447
   PubMed Web of Science ®Google Scholar
• Park Y-S, Sung-Jin Hong MD, Boo Y-K Ph.D, et al. The National Status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis (Seoul). 2012;73(1):48–55. doi:10.4046/trd.2012.73.1.4823101024
   PubMedGoogle Scholar
• Chuang P-H, Wu M-H, Fan S-Y, Lin K-Y, Jou R, Sola C. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007–2014. PLoS One. 2016;11(11):e0165222. doi:10.1371/journal.pone.016522227846235
   PubMed Web of Science ®Google Scholar
• Wua B, Zhangb L, Liua Z, et al. Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999–2013. Glob Health Action. 2017;10(1):1293925. doi:10.1080/16549716.2017.129392528578621
   PubMed Web of Science ®Google Scholar
• Prasad R, Gupta N, Banka A. Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: principles of management. Lung India. 2018;35(1):78–81. doi:10.4103/lungindia.lungindia_98_1729319042
   PubMed Web of Science ®Google Scholar
• Su WJ, Feng JY, Huang CC, Perng RP. Increasing drug resistance of Mycobacterium tuberculosis isolates in a medical center in northern Taiwan. J Formos Med Assoc. 2008;107:259–264. doi:10.1016/S0929-6646(08)60145-X18400612
   PubMed Web of Science ®Google Scholar
• Liaw YS, Hsueh PR, Yu CJ, Wang SK, Yang PC, Luh KT. Drug resistance pattern of Mycobacterium tuberculosis in a university hospital in Taiwan, 1998–2002. J Formos Med Assoc. 2004;103:671–6779.15361939
   PubMed Web of Science ®Google Scholar
• Yu MC, Suo J, Chiang CY, Bai KJ, Lin TP, Luh KT. Initial drug resistance of Mycobacterium tuberculosis in Taiwan. J Formos Med Assoc. 1997;96:890–894.9409122
   PubMed Web of Science ®Google Scholar
• Liu W-L, Lai -C-C, Tan C-K, et al. Declining drug resistance of Mycobacterium tuberculosis isolates from elderly patients in Taiwan, 2000–2008. Eur J Clin Microbiol Infect Dis. 2010;29(11):1413–1416. doi:10.1007/s10096-010-1019-720652344
   PubMed Web of Science ®Google Scholar
• Djuretic T, Herbert J, Drobniewski F, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993–1999. Thorax. 2002;57:477–482. doi:10.1136/thorax.57.6.47712037221
   PubMed Web of Science ®Google Scholar
• Jia X, Chen J, Zhang S, Dai B, Long Q, Tang S. Implementing a “free” tuberculosis (TB) care policy under the integrated model in Jiangsu, China: practices and costs in the real world. Infect Dis Poverty. 2016;5(1):1. doi:10.1186/s40249-016-0099-826796785
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet. 2014;383(9934):2057–2064. doi:10.1016/S0140-6736(13)62639-224650955
   PubMed Web of Science ®Google Scholar
• Wang L Prof, Liu J MD, Chin DP Dr. Progress in tuberculosis control and the evolving public-health system in China. Lancet. 2007;369(9562):691–696. doi:10.1016/S0140-6736(07)60316-X17321314
   PubMed Web of Science ®Google Scholar
• Kempker RR, Rabin AS, Nikolaishvili K, et al. Additional drug resistance in mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis. 2012;54(6):e51–e54. doi:10.1093/cid/cir90422198790
   PubMed Web of Science ®Google Scholar
• Adejumo OA, Olusola-Faleye B, Adepoju V, et al. Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria. Afri Health Sci. 2018;18(3):472–478. doi:10.4314/ahs.v18i3.2
   Web of Science ®Google Scholar
• Li D, He W, Chen B, Lv P. Primary multidrug-resistant tuberculosis versus drug sensitive tuberculosis in non-HIV-infected patients: comparisons of CT findings. PLoS One. 2017;12(6):e0176354. doi:10.1371/journal.pone.017635428586348
   PubMed Web of Science ®Google Scholar
• Dheda K, Lenders L, Magombedze G, et al. Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. Am J Respir Crit Care Med. 2018;198(9):1208–1219. doi:10.1164/rccm.201711-2333OC29877726
   PubMed Web of Science ®Google Scholar
• Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol. 2010;5(2):96–114. doi:10.2174/15748841079111079720156156
   PubMedGoogle Scholar
• Kaplan G, Post FA, Moreira AL, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003;71(12):7099–7108. doi:10.1128/iai.71.12.7099-7108.200314638800
   PubMed Web of Science ®Google Scholar